Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study

BACKGROUND: Tenofovir alafenamide (TAF) is a novel tenofovir prodrug with improved renal and bone safety compared with TDF-containing regimens. We report the 48 week safety and efficacy of a once-daily single tablet regimen of elvitegravir 150 mg (E), cobicistat 150 mg (C), emtricitabine 200 mg (F),...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:J Acquir Immune Defic Syndr
Κύριοι συγγραφείς: Pozniak, Anton, Arribas, Jose R., Gathe, Joseph, Gupta, Samir K., Post, Frank A., Bloch, Mark, Avihingsanon, Anchalee, Crofoot, Gordon, Benson, Paul, Lichtenstein, Kenneth, Ramgopal, Moti, Chetchotisakd, Ploenchan, Custodio, Joseph M., Abram, Michael E., Wei, Xuelian, Cheng, Andrew, McCallister, Scott, SenGupta, Devi, Fordyce, Marshall W.
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: JAIDS Journal of Acquired Immune Deficiency Syndromes 2016
Θέματα:
Clinical Science
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4804743/
https://ncbi.nlm.nih.gov/pubmed/26627107
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/QAI.0000000000000908
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια